Bacteria and their endotoxins often cause excessive inflammatory responses. This can be seen in various types of wounds, such as burn wounds, post-surgical wounds and in non-healing ulcers. In2cure AB develops proprietary peptides for prevention and treatment of wound and surgical complications and aims to develop novel treatments based on nature’s own defenses – evolutionary old biological systems which normally keep us healthy. The lead candidate TCP-25 is part of nature´s own host defense, and the focus is to utilize it’s proven anti-endotoxic properties in functionalized biomaterials and new wound formulations. In2cure is currently evaluating other applications of its BioC formulation platform for various therapeutic uses. In2cure´s product BioC has a strong scientific base with several publications in international journals.